By TOM MURPHY, AAMER MADHANI and JONEL ALECCIA, Associated Press

WASHINGTON (AP) — President Donald Trump unveiled a deal Thursday with drugmakers Eli Lilly and Novo Nordisk to expand coverage and reduce prices for their popular obesity treatments Zepbound and Wegovy.

Related Articles

The drugs are part of a new generation of obesity medications known as GLP-1 receptor agonists that have soared in popularity in recent years.

But access to the drugs has been a consistent problem for patients because of their cost — around $500 a month for higher doses — and insurance coverage has been spotty.

Coverage of the drugs for obesity will expand to Medicare patients starting next year, according to the administration, which said some lower prices also will be phased in for patients without cov

See Full Page